Ponatinib

Iclusig (Ponatinib)

Iclusig

Ponatinib

10 mg/15 mg/30 mg/45 mg

Ariad Pharmaceuticals, Inc.

Medical Use

Iclusig (ponatinib) is a kinase inhibitor used to treat adult patients with:

  • -Chronic phase (CP) chronic myeloid leukemia (CML) who have shown resistance or intolerance to at least two prior kinase inhibitors.
  • -Accelerated phase (AP) or blast phase (BP) CML or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) when no other kinase inhibitors are suitable.
  • -T315I-positive CML (chronic, accelerated, or blast phase) or T315I-positive Ph+ ALL.

Recommended Dosage:

  • -CP-CML: Start with 45 mg orally once daily, with or without food. Reduce to 15 mg once daily upon achieving a molecular response (≤1% BCR-ABL1IS). If response is lost, the dose can be increased back to 30 mg or 45 mg once daily. Continue treatment until response is lost again or unacceptable toxicity occurs. Consider stopping treatment if no hematologic response is seen within three months.
  • -AP-CML, BP-CML, and Ph+ ALL: Start with 45 mg orally once daily, with or without food. Continue until response is lost or unacceptable toxicity occurs. Dose reduction may be considered for AP-CML patients who achieve a major cytogenetic response. Discontinue treatment if no response is seen within three months.

Copyright © 2023 GRPPL Group . | All rights Reserved.